Also read India’s quest to fix its payments puzzleThe FDA has also scheduled a meeting of an outside advisory committee for Dec.
10 to review the test data, which Dr. Hahn said was another step taken to assure the public amid concerns that the FDA might rush approval.“We realize there is an issue in the U.S.
around vaccine hesitancy. There have been concerns raised about the speed with which Covid-19 vaccines have been developed," Dr.
Hahn said. “This will meet our gold standard of safety and efficacy that the American people have come to trust."Dr. Hahn’s comments came on the day that British regulators cleared the Pfizer vaccine for general distribution.